Kalobios Pharmaceuticals
South San Francisco, US · Delaware corporation
Find your way into Kalobios Pharmaceuticals
Sign up to see every warm intro you have to Kalobios Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Kalobios Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
Board
DM
David MoradiBoard director
MH
Michael HarrisonBoard director
Reported raises · per SEC filings
Form D private placements$22.2M disclosed across 5 rounds · 2015–2019
▶$494.6KraisedNov 2019 · 1 investors · PharmaceuticalsRule 506(b)
▶$494.6KraisedNov 2019 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Cameron DurrantExecutive Officer, Director
- Ronald BarliantDirector
- Rainer BoehmDirector
- Robert SavageDirector
- Timothy MorrisDirector
- Offering amount
- $20.5M
- Amount sold
- $494.6K
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedMay 2019 · 11 investors · PharmaceuticalsRule 506(b)
▶$1.3MraisedMay 2019 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Greg JesterExecutive Officer
- Rainer BoehmDirector
- Robert SavageDirector
- Timothy MorrisDirector
- Ronald BarliantDirector
- Cameron DurrantExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1.3M
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15KraisedSep 2017 · 1 investors · PharmaceuticalsRule 506(b)
▶$15KraisedSep 2017 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Greg JesterExecutive Officer
- Ezra FriedbergDirector
- Timothy MorrisDirector
- Ronald BarliantDirector
- Dale ChappellDirector
- Morgan LamExecutive Officer
- Cameron DurrantExecutive Officer, Director
- Offering amount
- $15M
- Amount sold
- $15K
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.2MraisedJul 2016 · 8 investors · PharmaceuticalsRule 506(b)
▶$12.2MraisedJul 2016 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Morgan LamExecutive Officer
- Dale ChappellDirector
- Dean Witter IIIExecutive Officer
- Timothy MorrisDirector
- Ezra FriedbergDirector
- Cameron DurrantExecutive Officer, Director
- Ronald BarliantDirector
- Offering amount
- $12.2M
- Amount sold
- $12.2M
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.2MraisedJan 2016 · 18 investors · PharmaceuticalsRule 506(b)
▶$8.2MraisedJan 2016 · 18 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David MoradiDirector
- Michael HarrisonDirector
- Offering amount
- $8.8M
- Amount sold
- $8.2M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Kalobios Pharmaceuticals raised?
- Kalobios Pharmaceuticals has disclosed $22.2M raised across 5 rounds.
- Where is Kalobios Pharmaceuticals headquartered?
- Kalobios Pharmaceuticals is headquartered in South San Francisco, US.